Penumbra (NYSE:PEN) announced today that the Cheetah clinical study for its Indigo CAT RX catheter met its primary endpoint.
Alameda, California-based Penumbra’s Indigo catheter system demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in patients with high thrombus burden.